BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Sep 06, 2010
 |  BC Week In Review  |  Company News  |  Deals

Genzyme, sanofi-aventis deal

Genzyme rejected an unsolicited offer from sanofi-aventis to acquire the company for $69 per share in cash, or about $18.5 billion. The offer is identical to one proposed privately on July 29; Genzyme rejected that offer on Aug. 11. The price is a 27% premium to Genzyme's close of...

Read the full 222 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >